anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A. Participants. Study participants with masked hypertension (MH) with controlled clinic BP (\< 130/80 mmHg) and uncontrolled out-of-clinic awake ambulatory BP (ABP ≥ 130/80 mmHg) untreated with antihypertensive medications will be recruited.

B. Study design. This is a double-blinded, randomized, 2-period, 2-treatment crossover clinical trial comparing sympatholytic antihypertensive agent (αβ-blocker - carvedilol 40mg extended release once daily) with non-sympatholytic control agent (dihydropyridine calcium channel blocker - amlodipine 10mg once daily) in individuals with MH. All study participants will undergo out-of-clinic 24hr ABP with actigraphy monitoring for 24-hr, awake and asleep ABP; sympathetic activity assessment by BP and HR variability, 24-hour urinary catecholamines and metanephrines at baseline and after intervention. In order to avoid selection bias, patients will be randomized to their initial therapy. Patients and study personnel will be blinded to the treatment group in order to minimize information bias. An investigator without direct study involvement will be assigned the task of ensuring correct dispensing of the study medication, which will be prepared as matching capsules by the UAB Pharmacy - Investigational Drug Service. After 4 weeks of initial treatment, both treatment groups will undergo a 1-month washout where no study medication is given in order to prevent a carryover effect. The study medication will be taken in the morning between 6 and 9 am except for study visit days. A crossover design is chosen to minimize differences between study groups, as participants will act as their own controls. Electrolytes, kidney function and ECG will be monitored at each visit. Medication adherence will be determined at visit 2 (week 4) and visit 4 (week 12) by measuring 24-hr urinary specimens for medications and their metabolites by LC-MS/MS and by pill count and medication log.

C. Outcomes. The primary outcome is the difference in percent change in out-of-clinic mean 24-hr ABP, awake ABP and asleep ABP with carvedilol compared to amlodipine. Secondary outcomes include change in out-of-clinic sympathetic activity by BP and HR variability; and 24-hour urinary catecholamines and metanephrines.

D. Preliminary / anticipated results. We anticipate a greater reduction in out-of-clinic 24-hr, awake and asleep ABP due to blocking of sympathetic activity with carvedilol when compared to amlodipine use in individuals with MH. A statistically significant effect estimate will support our hypothesis that higher sympathetic activity contributes to MH, which can be managed by use of sympatholytic agents like carvedilol.
SARS-CoV-2 has caused severe illness and anxiety worldwide, evolving into more dreadful variants capable of evading the host's immunity. Cytokine storms, led by PI3Kγ, are common in cancer and SARS-CoV-2. Naturally, there is a yearning to see whether any drugs could alleviate cytokine storms for both. Upon investigation, we identified two anticancer drugs, Duvelisib and Eganelisib, that could also work against SARS-CoV-2. This report is the first to decipher their synergic therapeutic effectiveness against COVID-19 and cancer with molecular insights from atomistic simulations. In addition to PI3Kγ, these drugs exhibit specificity for the main protease among all SARS-CoV-2 targets, with significant negative binding free energies and small time-dependent conformational changes of the complexes. Complexation makes active sites and secondary structures highly mechanically stiff, with barely any deformation. Replica simulations estimated large pulling forces in enhanced sampling to dissociate the drugs from Mpro's active site. Furthermore, the radial distribution function (RDF) demonstrated that the therapeutic molecules were closest to the His41 and Cys145 catalytic dyad residues. Finally, analyses implied Duvelisib and Eganelisib as promising dual-purposed anti-COVID and anticancer drugs, potentially targeting Mpro and PI3Kγ to stop virus replication and cytokine storms concomitantly. We also distinguished hotspot residues imparting significant interactions.
The present invention relates to medicine for treating yperplasia of mammary glands and a preparation method thereof, which belongs to the field of traditional Chinese medicine. The medicine of the present invention uses Chinese herbal medicine snakegourd fruit, scorpion, centipede, bee, Chinese honeylocust spine and pangolinscale as raw materials, wherein the composition of the raw materials is 400 to 600 shares of snakegourd fruit, 40 to 60 shares of scorpion, 20 to 40 shares of centipede, 20 to 40 shares of bee, 10 to 20 shares of Chinese honeylocust spine and 10 to 20 shares of pangolinscale. The medicine of the present invention has the effect of accumulation of pathogen dispersion, pain alleviation, reuscitation induction, stagnatin absorption, channel activation, blood activation, chest relieving, phlegm resolving, etc. Meanwhile, the present invention has the functions of liver and spleen regulation, heart and kidney coordination, bowel relaxation and increase of the immunological function, etc. The medicine of the present invention has the advantages of effective and few prescription, simple and unique preparation technology, low cost convenient carrying and administration, outstanding curative effect, high cure rate, safety, no toxic side effect, obvious effect and no relapse after cure. The clinic cure rate can reach 88%, the total effective rate can reach more than 97%, and the present invention can generate larger economical and social benefits after popularization and can benefit to human.
It is crucial that future physicians understand the nature of opioid use disorder (OUD). We designed a pilot Observed Structured Clinical Examination (OSCE) using simulated patients (SPs) experiencing OUD with concurrent chronic pain. The case was piloted in 2021 and 2022 during the multi-station OSCE that all the medical school clerkship students take at the end of their third year of medical school. A total of 111 medical students completed the OSCE in 2021 and 93 in 2022. The authors developed a case description and an assessment instrument for the SP to evaluate the student's performance on history taking, communication and professionalism. The evaluation was mixed-methods using SP evaluation data and a qualitative assessment of medical students' answers to 4 questions which were analyzed with a priori codes. In both years, the total scores for the case were slightly slower than the established OSCE cases in both years. A total of 75% (148/197) of students who responded to the assessment found the case difficult to manage. Strengths of the case included a majority of the students reporting the case helped them to identify strengths and weakness in assessing and treating OUD. Weaknesses included the lack of enough patient history and the perception that the SP was unrealistic (too nice). This pilot OSCE was challenging for the third year medical students based on the evaluative data. Given the scope of OUD and deaths, training students to identify and treat OUD during undergraduate medical education is of paramount importance.
Gastrointestinal (GI) disruptions and inflammatory bowel disease (IBD) are commonly associated with Parkinson's disease (PD), but how they may impact risk for PD remains poorly understood. Herein, we provide evidence that prodromal intestinal inflammation expedites and exacerbates PD endophenotypes in rodent carriers of the human PD risk allele LRRK2 G2019S in a sex-dependent manner. Chronic intestinal damage in genetically predisposed male mice promotes α-synuclein aggregation in the substantia nigra, loss of dopaminergic neurons and motor impairment. This male bias is preserved in gonadectomized males, and similarly conferred by sex chromosomal complement in gonadal females expressing human LRRK2 G2019S. The early onset and heightened severity of neuropathological and behavioral outcomes in male LRRK2 G2019S mice is preceded by increases in α-synuclein in the colon, α-synuclein-positive macrophages in the colonic lamina propria, and loads of phosphorylated α-synuclein within microglia in the substantia nigra. Taken together, these data reveal that prodromal intestinal inflammation promotes the pathogenesis of PD endophenotypes in male carriers of LRRK2 G2019S, through mechanisms that depend on genotypic sex and involve early accumulation of α-synuclein in myeloid cells within the gut.
In a placebo-controlled clinical trial of patients with RA, no difference was detected in anti-pneumococcal antibody response between adalimumab and placebo treatment groups when the pneumococcal polysaccharide vaccine and influenza vaccine were administered concurrently with adalimumab. Similar proportions of patients developed protective levels of anti-influenza antibodies between adalimumab and placebo treatment groups; however, titers in aggregate to influenza antigens were moderately lower in patients receiving adalimumab. The clinical significance of this is unknown. Patients on SIMLANDI may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving adalimumab products.

It is recommended that pediatric patients, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating SIMLANDI therapy. Patients on SIMLANDI may receive concurrent vaccinations, except for live vaccines.

The safety of administering live or live-attenuated vaccines in infants exposed to adalimumab products in utero is unknown. Risks and benefits should be considered prior to vaccinating (live or live-attenuated) exposed infants [see Use in Specific Populations (8.1, 8.4)].
Healthy participants (creatinine clearance \[CLcr\] ≥80 mL/min) take 2 MK-362B FDC tablets on Day 1 after fasting for 10 hours. Healthy participants are matched to RI participants based on mean age, body mass index (BMI) and gender.
Patients will receive 12 weeks TMC435 100 mg once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV), followed by PegIFNα-2a and RBV alone. Response-guided treatment criteria will be used to determine total treatment duration of 24 or 48 weeks for patients in the TMC435 treatment groups. Patients in the control group will continue PegIFNα-2a and RBV until Week 48.
The intervention group will receive usual care and the PATCH intervention. The intervention is comprised of two phases in which the in-hospital discharge education session is followed by 12 weeks of post-discharge education sessions delivered by telephone. The focus of this study is to test the mechanism of the proposed patient activation intervention on HF self-management adherence and associated health outcomes.
Acute kidney injury (AKI) is a common and devastating complication of hospitalization. Here, we identified genetic loci associated with AKI in patients hospitalized between 2002-2019 in the Million Veteran Program and data from Vanderbilt University Medical Center's BioVU. AKI was defined as meeting a modified KDIGO Stage 1 or more for two or more consecutive days or kidney replacement therapy. Control individuals were required to have one or more qualifying hospitalizations without AKI and no evidence of AKI during any other observed hospitalizations. Genome-wide association studies (GWAS), stratified by race, adjusting for sex, age, baseline estimated glomerular filtration rate (eGFR), and the top ten principal components of ancestry were conducted. Results were meta-analyzed using fixed effects models. In total, there were 54,488 patients with AKI and 138,051 non-AKI individuals included in the study. Two novel loci reached genome-wide significance in the meta-analysis: rs11642015 near the FTO locus on chromosome 16 (obesity traits) (odds ratio 1.07 (95% confidence interval, 1.05-1.09)) and rs4859682 near the SHROOM3 locus on chromosome 4 (glomerular filtration barrier integrity) (odds ratio 0.95 (95% confidence interval, 0.93-0.96)). These loci colocalized with previous studies of kidney function, and genetic correlation indicated significant shared genetic architecture between AKI and eGFR. Notably, the association at the FTO locus was attenuated after adjustment for BMI and diabetes, suggesting that this association may be partially driven by obesity. Both FTO and the SHROOM3 loci showed nominal evidence of replication from diagnostic-code-based summary statistics from UK Biobank, FinnGen, and Biobank Japan. Thus, our large GWA meta-analysis found two loci significantly associated with AKI suggesting genetics may explain some risk for AKI.
PURPOSE:To obtain a suppository composition having high releasability of drug from a base and high absorption of drug from rectal mucosa, containing nicotinic ester, diphenhydramine, etc., and a water-insoluble solid drug. CONSTITUTION:A suppository composition containing (A) a substance selected from nicotinic ester, salicylic ester, diphenhydramine, crotamiton, benzyl alcohol and a mixture of menthol and camphor and (B) a water-insoluble solid drug such as steroid anti-inflammatory drug (e.g. hydrocortisone), nonsteroid anti- inflammatory drug (e.g. glycyrrhetinic acid, etc.) or local anesthetic (e.g. procaine) in a ratio of 0.05-2.0wt.% based on total composition of the component B and 5-60pts.wt. of the component A based on 1pt.wt. component B. The suppository has excellent immediate effects and improved treating effects.
Objective: This study aims to explore the preventive potential of photobiomodulation (PBM) in bisphosphonate-related osteonecrosis of the jaw (BRONJ) using a rat model. Methods: An experimental rat model was established, exposing rats to zoledronic acid (ZA), a primary risk factor for BRONJ. An 810 nm diode laser was applied with parameters of 0.33 W/cm2 power density and 10 J/cm2 energy density for 30 sec. PBM was initiated 1 day pre-extraction and continued for 2 weeks. The impact of PBM on wound healing in both soft and hard tissues was evaluated post tooth extraction. Results: ZA exposure hindered wound healing in both soft and hard tissues after tooth extraction. PBM intervention effectively mitigated the adverse effects of ZA, promoting healing processes in both tissue types. This suggests the potential of PBM as a preventive strategy for BRONJ in patients on long-term bisphosphonate treatment. Moreover, PBM exhibited enhanced wound healing in normal rats, indicating its broader applicability beyond BRONJ cases. Conclusions: PBM shows promise in preventing and improving wound healing in BRONJ and normal cases. These findings underscore the significance of optimizing PBM parameters and suggest its potential clinical relevance as a preventive intervention for BRONJ and a promoter of wound healing.
Type 2 diabetes mellitus (T2DM) remains a global health concern despite current treatment options. This study investigated the potential of Tapinanthus cordifolius (TC) leaf extract as a therapeutic agent for T2DM. T2DM was induced in rats using a high-fat diet and streptozotocin. Diabetic rats received daily oral administration of TC extract (200, 400, or 800 mg/kg) and metformin (400 mg/kg) or remained untreated for 21 days. Blood glucose levels, body weight, diabetic symptoms, oxidative stress markers, and gene expression of metabolic regulators were assessed. TC treatment significantly reduced blood glucose levels and restored body weight in diabetic rats, comparable to the effects of metformin. TC also increased antioxidant enzyme activities (SOD, GST, and CAT) and decreased lipid peroxidation in various tissues. Furthermore, TC upregulated gene expression of glucose transporter type 4 (GLUT-4) and adiponectin receptor 2 (ADIPOR-2) while downregulating pro-inflammatory cytokines TNF-α and IL-6. This study provides the first in vivo evidence supporting TC leaf extract's anti-diabetic and antioxidant efficacy. The findings suggest that TC holds promise as a natural therapeutic agent for managing T2DM through multiple mechanisms, including improved glycemic control, enhanced insulin sensitivity, and protection against oxidative stress and tissue damage. In conclusion, this study validates the ethnobotanical use of TC as an anti-diabetic agent. Further research is warranted to isolate the bioactive compounds responsible for these effects.
The invention is directed to a device and method for delivering a therapeutic substance (64) to a bodily tissue in a minimally invasive manner. The device includes an elongate flexible tubular member (12) having a proximal end (14) and a distal end (16). A control lever (50) is provided for enabling the distal end (16) of the tubular member (12) to be controllably flexed in a transverse manner for positioning the distal end (16) of the tubular member (12) proximate to the bodily tissue to be treated. A hollow needle (62) is disposed at the distal end (16) of the tubular member (12) for delivering the therapeutic substance (64) into the bodily tissue. A marking device (78) is also included for indicating the location where an injection has been made in the tissue. This enables the surgeon to keep track of the areas in which injections are made so that the therapeutic substance (64) may be evenly distributed over a desired area of treatment. A method for using the device is also disclosed wherein a patient's lung (120) is partially collapsed to enable access to areas of the heart (128). The therapeutic substance (64) may be injected into the patient's myocardium (138) by passing the needle (62) directly through the patient's pericardium (126). The invention is particularly useful for treatment of ischemic heart disease by gene therapy.
This study is a randomized controlled trial of CPT compared to waitlist control that is testing the effects of CPT on mechanisms of the PTSD-CVD link. Enrollment began in 2023 and is projected to continue through 2026. Participants include individuals with PTSD and CVD risk recruited from the Boston area (N = 30). Treatment assignment is randomized and stratified by sex. Participants are randomized to CPT (n = 15) or waitlist control (n = 15). Potentially eligible participants complete a screening visit to confirm inclusion/exclusion criteria. Upon confirmation of eligibility, participants are scheduled for a baseline session, where they complete surveys, brain and peripheral imaging, and resting measures of autonomic function. Following the baseline visit, participants are randomized into CPT or the waitlist control group. Those randomized to CPT complete sessions via telehealth. Following a 12-week treatment period, participants attend the post-treatment visit, consisting of the same assessments administered at baseline. Participants randomized to waitlist are offered CPT upon completion of the post-treatment visit.
The invention relates to a looks-improving, youth-keeping and anti-aging health care food which can strengthen human immunity function and a preparation method thereof. The health care food compounds donkey hide gelatin, polygonatum, poria cocos, cassis seed, rhizoma polygonatum, wolfberry fruit, etc. raw materials in accordance with a certain portion. The raw materials are made into oral liquid, granule or tea drinking through the preparation technique of cleaning, precise selection, processing, grinding, etc. The health care food of the invention, based on the theory of keeping health of Chinese traditional medicine, has the functions of conserving outside with inside, looks improving and youth keeping, delaying aging and strengthening the immunity function of human body. The raw materials of the invention are natural, atoxic and harmless and do not have side effects; meanwhile, the source of the raw materials is sufficient. The preparation method is scientific and reasonable, simple and easy.
PURPOSE:To make it possible to determine a substance having colony forming ability in a short time and automatically, by measuring absorbance of a formazan compound produced by participation of mitochondria in a mouse myeloid cell. CONSTITUTION:In a method of measuring colony stimmulating factor by treating a mouse myeloid cell with a colony stimmulating factor and multiplying the cell, first, a tetrazolium compound is converted into a formazan compound by participartion of mitochondria in the cell. Then absorbance of the formed formazan compound is measured to determine activity of the colony stimmulating factor. The above-mentioned measuring method can be usually carried out as follows. (a) The tetrazolium compound is added to the multiplied mouse myeloid cells and (b) the tetrazolium compound is converted into the formazan compound in the cells by participation of mitochondria. (c) The formazan compound is eluted in the cells, homogenized and (d) absorbance of the eluted formazan compound is measured.
The present invention relates to blood fat reducing and liver protecting medicine prepared from a cassia seed extract. A medicinal substance is an ethyl acetate extract of cassia seeds. The ethyl acetate extract is prepared into tablets, pills, capsules, granules or oral liquid by adopting a medicinal supplementary material according to the conventional technology. The medicinal dosage of the medicine is between 0.03 g.kg<-1>. d<-1> and 0.30 g.kg<-1>. d<-1>. The ethyl acetate extract of cassia seeds has an obvious effect for reducing blood fat to the testing hyperlipemia of mice and rats, and can reduce the fat content of livers, relieve or eliminate the pathological damage of the fatty liver, and improve the functions of the livers when reducing the blood fat. The ethyl acetate extract is superior to any extract of other solvents of the same dosage. The blood fat reducing and liver protecting medicine prepared from the ethyl acetate extract has the advantages of obvious therapeutic effect, little taking dosage, simple technology and low comprehensive cost. Besides, a solvent, namely ethyl acetate, can be recovered and reused. The present invention is novel blood fat reducing and liver protecting medicine which can be used for the treatment of reducing blood fat for a long time.
The purpose of this study; To investigate the effects of Clinical Pilates and Tai Chi exercises on glycemic control, body composition, balance function and physical activity level in individuals with prediabetes. Method: 54 individuals diagnosed with Prediabetes in the Endocrinology and Metabolic Diseases Polyclinic at Niğde Ömer Halisdemir Training and Research Hospital will participate in our study. Individuals will be divided into 3 groups: Clinical Pilates group, Tai Chi group and control group. Before exercise, routine blood tests of individuals will be performed and their fasting and postprandial blood glucose and HbA1C (Glycosized Hemoglobin) levels will be checked. Bioelectrical Impedance Device will be used to evaluate body composition. Timed Up and Go Test and Berg Balance Scale will be used to evaluate individuals' balance functions. Physical Activity level of individuals will be measured using the International Physical Activity Level Scale (IPAQ) and the Accelerometer device. Evaluations will be repeated in all groups at the end of the 12-week exercise application. SPSS (Statistical Package Program for Social Science) software will be used to analyze the data. Statistical analysis of the study will be done with Wilcoxon related two-sample test for intra-group measurements, and Man Whitney U test for inter-group evaluations. For the significance level, p value will be accepted as p\<0.05.